William Kemnitzer,
Shailaja Kasibhatla,
Songchun Jiang,
Hong Zhang,
Jianghong Zhao,
Shaojuan Jia,
Lifen Xu,
Candace Crogan-Grundy,
Réal Denis,
Nancy Barriault,
Louis Vaillancourt,
Sylvie Charron, Jennifer Dodd,
Giorgio Attardo,
Denis Labrecque,
Serge Lamothe,
Henriette Gourdeau,
Ben Tseng,
John Drewe,
Sui Xiong Cai
[show abstract]
[hide abstract]
ABSTRACT: As a continuation of our efforts to discover and develop the apoptosis inducing 4-aryl-4H-chromenes as novel anticancer agents, we explored the SAR of 4-aryl-4H-chromenes with modifications at the 7- and 5-, 6-, 8-positions. It was found that a small hydrophobic group, such as NMe2, NH2, NHEt, and OMe, is preferred at the 7-position. Di-substitution at either the 5,7-positions or the 6,7-positions generally led to a large decrease in potency. Di-substitution at the 7,8-positions, in general, was found to result in potent compounds. 7-NMe2, 7-NHEt, 7-OMe, and 7,8-di-NH2 analogs were found to have similar SAR for the 4-aryl group, and several 7-substituted and 7,8-di-substituted analogs were found to have similar potencies as the lead compound MX58151 (2a) both as caspase activators and inhibitors of cell proliferation.
Bioorganic & Medicinal Chemistry Letters 12/2005; 15(21):4745-51. · 2.55 Impact Factor
